SEARCH

SEARCH BY CITATION

References

  • 1
    Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 1994; 91: 11981205.
  • 2
    Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 24892499.
  • 3
    Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15: 431439.
  • 4
    Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 3455.
  • 5
    Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 13751383.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 7
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 8
    Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 17111719.
  • 9
    Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte- derived interferon. J Clin Endocrinol Metab 1986; 63: 10861090.
  • 10
    Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985; 1: 1166.
  • 11
    Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13: 547551.
  • 12
    Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997; 7: 891896.
  • 13
    Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101: 482487.
  • 14
    Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132: 587593.
  • 15
    Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. HEPATOLOGY 2002; 36: 12801284.
  • 16
    Mazziotti G, Sorvillo F, Stornaiuolo G, Rotondi M, Morisco F, Ruberto M, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002; 25: 624630.
  • 17
    Villanueva RB, Brau N. Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid 2002; 12: 737738.
  • 18
    Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit 2001; 7( Suppl 1): 221225.
  • 19
    Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev 2004; 3: 388393.
  • 20
    Davies TF. Graves' Diseases: Pathogenesis. In: BravermanLE, UtigerRD, editors. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000: 518530.
  • 21
    Weetman AP. Chronic autoimmune thyroiditis. In: BravermanLE, UtigerRD, eds. Werner and Ingbar's The thyroid. Philadelphia: Lippincott Williams and Wilkins, 2000: 721732.
  • 22
    Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223243.
  • 23
    Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489499.
  • 24
    Tomer Y, Ban Y, Concepcion E, Barbesino G, Villanueva R, Greenberg DA, et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: Results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet 2003; 73: 736747.
  • 25
    Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: From gene mapping to gene function. Endocr Rev 2003; 24: 694717.
  • 26
    Tomer Y, Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link? Am J Med 2004; 117: 6061.
  • 27
    Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995; 43: 5568.
  • 28
    Kohno T, Tsunetoshi Y, Ishikawa E. Existence of anti-thyroglobulin IgG in healthy subjects. Biochem Biophys Res Comm 1988; 155: 224229.
  • 29
    Ericsson UB, Christensen SB, Thorell J. A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid diesase as measured with a sensitive solid- phase immunosorbent radioassay. Clinical Immunology and Immunopathology 1985; 37: 154162.
  • 30
    Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002; 56: 793798.
  • 31
    Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 21552160.
  • 32
    Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993; 39: 657661.
  • 33
    Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001; 86: 19251929.
  • 34
    Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994; 89: 399403.
  • 35
    Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa J, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995; 80: 922926.
  • 36
    Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995; 44: 110114.
  • 37
    Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44: 635642.
  • 38
    Martocchia A, Labbadia G, Paoletti V, Gargano S, Grossi A, Trabace S, et al. Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinol Lett 2001; 22: 4952.
  • 39
    Deutsch M, Koskinas J, Tzannos K, Vassilopoulos D, Mailis A, Tolis G, et al. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin. Ann Pharmacother 2005; 39: 17451747.
  • 40
    Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 2005; 115: 19721983.
  • 41
    Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Eng J Med 1993; 329: 14681475.
  • 42
    Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168199.
  • 43
    Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004; 3: 199210.
  • 44
    Volpe R. Etiology, pathogenesis, and clinical aspects of thyroiditis. Pathol Annu 1978; 13: 399413.
  • 45
    Weetman AP, Smallridge RC, Nutman TB, Burman KD. Persistent thyroid autoimmunity after subacute thyroiditis. J Clin Lab Immunol 1987; 23: 16.
  • 46
    Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat 2000; 7: 393395.
  • 47
    Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283291.
  • 48
    Tomer Y, Davies TF. Infection, Thyroid Disease and Autoimmunity. Endocr Rev 1993; 14: 107120.
  • 49
    Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu GL, Farci P, et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia. J Endocrinol Invest 1999; 22: 660665.
  • 50
    Metcalfe RA, Ball G, Kudesia G, Weetman AP. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 1997; 7: 421424.
  • 51
    Boadas J, Rodriguez-Espinosa J, Enriquez J, Miralles F, Martinez-Cerezo FJ, Gonzalez P, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol 1995; 22: 611615.
  • 52
    Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. HEPATOLOGY 1993; 18: 253257.
  • 53
    Ganne-Carrie N, Medini A, Coderc E, Seror O, Christidis C, Grimbert S, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun 2000; 14: 189193.
  • 54
    Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 14451448.
  • 55
    Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 1013.
  • 56
    Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1993; 17: 417419.
  • 57
    Tunbridge WMG, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol Oxf 1977; 7: 481493.
  • 58
    Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002; 146: 743749.
  • 59
    Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002; 251: 400406.
  • 60
    Barbesino G, Tomer Y, Concepcion ES, Davies TF, Greenberg D. Linkage analysis of candidate genes in autoimmune thyroid disease: 2. Selected gender-related genes and the X-chromosome. J Clin Endocrinol Metab 1998; 83: 32903295.
  • 61
    Ansar AS, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985; 121: 531551.
  • 62
    Stenszky V, Kozma L, Balazs C, Rochkitz S, Bear JC, Farid NR. The genetics of Graves' disease: HLA and disease susceptibility. J Clin Endocrinol Metab 1985; 61: 735740.
  • 63
    Ban Y, Davies TF, Greenberg DA, Concepcion ES, Osman R, Oashi T, et al. Arginine at position 74 of the HLA-DRb1 chain is associated with Graves' disease. Genes Immun 2004; 5: 203208.
  • 64
    Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a caucasian population. J Clin Endocrinol Metab 1995; 80: 4145.
  • 65
    Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet 1999; 8: 11951199.
  • 66
    Tomer Y, Greenberg DA, Barbesino G, Concepcion ES, Davies TF. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001; 86: 16871693.
  • 67
    Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53: 30203023.
  • 68
    Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004; 89: 58625865.
  • 69
    Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A 2003; 100: 1511915124.
  • 70
    Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999; 30: 794800.
  • 71
    Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. HEPATOLOGY 2005; 42: 962973.
  • 72
    Sherman KE, Mendenhall C, Thee DL, O'Brien J, Rouster SD. Hepatitis C serotypes in nonalcoholic and alcoholic patients. Dig Dis Sci 1997; 42: 22852291.
  • 73
    Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. HEPATOLOGY 1999; 30: 265270.
  • 74
    Keenan ED, Rouster SD, Shire NJ, Horn PS, Sherman KE. Complexity and diversity of hepatitis C virus RNA in African Americans and whites: analysis of the envelope-coding domain. J Infect Dis 2004; 190: 511514.
  • 75
    Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142: 431437.
  • 76
    Zusinaite E, Metskula K, Salupere R. Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J Gastroenterol 2005; 11: 488491.
  • 77
    Codes L, de Freitas LA, Santos-Jesus R, Vivitski L, Silva LK, Trepo C, et al. Comparative study of hepatitis C virus genotypes 1 and 3 in Salvador, Bahia Brazil. Braz J Infect Dis 2003; 7: 409417.
  • 78
    Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999; 50: 503509.
  • 79
    Mekkakia-Benhabib C, Marcellin P, Colas-Linhart N, Castel-Nau C, Buyck D, Erlinger S, et al. [Natural history of dysthyroidism during interferon treatment of chronic hepatitis C]. Ann Endocrinol (Paris) 1996; 57: 419427.
  • 80
    Picardi A, Gentilucci UV, Zardi EM, D'Avola D, Amoroso A, Afeltra A. The role of ribavirin in the combination therapy of hepatitis C virus infection. Curr Pharm Des 2004; 10: 20812092.
  • 81
    Shiina M, Kobayashi K, Satoh H, Niitsuma H, Ueno Y, Shimosegawa T. Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C. J Gastroenterol Hepatol 2004; 19: 558564.
  • 82
    Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376382.
  • 83
    Tam RC, Lim C, Bard J, Pai B. Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. J Immunol 1999; 163: 37093717.
  • 84
    Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79(Pt 10): 23812391.
  • 85
    Corssmit EP, de Metz J, Sauerwein HP, Romijn JA. Biologic responses to IFN-alpha administration in humans. J Interferon Cytokine Res 2000; 20: 10391047.
  • 86
    Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002; 297: 20632066.
  • 87
    You X, Teng W, Shan Z. Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha. Chin Med J (Engl) 1999; 112: 6166.
  • 88
    Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 1997; 107: 359363.
  • 89
    Aulitzky WE, Tilg H, Vogel W, Aulitzky W, Berger M, Gastl G, et al. Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Ann Hematol 1991; 62: 2531.
  • 90
    Ajjan RA, Watson PF, McIntosh RS, Weetman AP. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol 1996; 105: 523528.
  • 91
    Sato K, Satoh T, Shizume K, Ozawa M, Han DC, Imamura H, et al. Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J Clin Endocrinol Metab 1990; 70: 17351743.
  • 92
    Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 2003; 115: 390397.
  • 93
    Lindahl P, Leary P, Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci U S A 1973; 70: 27852788.
  • 94
    De Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 1993; 77: 11201124.
  • 95
    Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 11851188.
  • 96
    Farrar JD, Murphy KM. Type I interferons and T helper development. Immunol Today 2000; 21: 484489.
  • 97
    Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 10171021.
  • 98
    Mazziotti G, Sorvillo F, Piscopo M, Morisco F, Cioffi M, Stornaiuolo G, et al. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab 2005; 90: 41384144.
  • 99
    Land KJ, Moll JS, Kaplan MH, Seetharamaiah GS. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism. Endocrinology 2004; 145: 37243730.
  • 100
    Mazziotti G, Sorvillo F, Carbone A, Cioffi M, Morisco F, Carella C. Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease? J Intern Med 2002; 252: 377378.
  • 101
    Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003; 170: 35223527.
  • 102
    Oppenheim Y, Kim G, Ban Y, Unger P, Concepcion E, Ando T, et al. The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse. Clin Dev Immunol 2003; 10: 161165.
  • 103
    Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005; 90: 11561162.
  • 104
    Yamazaki K, Kanaji Y, Shizume K, Yamakawa Y, Demura H, Kanaji Y, et al. Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab 1993; 77: 14391441.
  • 105
    Weetman AP. Graves' disease. N Engl J Med 2000; 343: 12361248.